Elan Corp, plc (ADR) (NYSE:ELN)
The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
TMFCop
(90.01)
Submitted: 1/21/2012 8:42:09 AM :
Start Price:
$13.23
ELN Score:
-5.04
New labeling and new tests for PML from Quest Diagnostics should open up even more markets -- and sales -- to Tysabri.
Recs
Coralreefer1
(32.90)
Submitted: 10/30/2011 4:04:18 AM :
Start Price:
$11.93
ELN Score:
+2.05
ELN swings to profits: Tysabri sales up 25%
Recs
CWKnob2
(< 20)
Submitted: 5/18/2011 1:43:17 PM :
Start Price:
$8.68
ELN Score:
+48.09
+The recent sale of the Micro crystals business shows me they have the cash flow from Tysrabi to finance their new Alzheimer's offering.
Recs
tommyboy1969
(< 20)
Submitted: 12/28/2010 6:49:04 PM :
Start Price:
$5.82
ELN Score:
+114.14
GUT PLAY
Recs
buckoblue31
(< 20)
Submitted: 10/30/2010 12:15:41 AM :
Start Price:
$5.44
ELN Score:
+123.37
Company has excelled in the past with it's tenacious performance with most of its trials. This kind of tynasity canot go unrewarded for to long a period.
Recs
mewag50
(< 20)
Submitted: 8/6/2010 6:34:45 PM :
Start Price:
$5.36
ELN Score:
+120.75
If not for poor management and many blunders by them, ELN would easily be well over $10 based on its science and pipeline, as well as Tysabri, which is well over $1 bil. and still has great growth potential.
Recs
QualityofLife
(< 20)
Submitted: 7/21/2010 12:47:16 PM :
Start Price:
$5.01
ELN Score:
-132.24
lack of effective leadership including the ceo and cfo.
Recs
anne1730
(62.23)
Submitted: 7/1/2010 5:54:25 PM :
Start Price:
$4.72
ELN Score:
+141.94
good product;; good research
Recs
asphall
(< 20)
Submitted: 6/11/2010 6:25:51 PM :
Start Price:
$5.11
ELN Score:
+129.90
too much taxes
Recs
Recs
watchit2
(< 20)
Submitted: 2/17/2010 4:41:51 AM :
Start Price:
$7.12
ELN Score:
-58.63
Dr.Paolo Zamboni has made a huge breakthrough in Multiple Sclerosis research. Sales of Tysabri will go down slow at first, then gain speed.
http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20091120/W5_liberation_091121/20091121?s_name=W5
Patients with Multiple Sclerosis and banding together to get tested and treated for Chronic Cerebral Spinal Insufficiency (CCSVI). Clinical trials already show a strong correlation between MS and CCSVI. A surgery (angioplasty or stents) on jugular veins are dramatically reducing symptoms of MS.
http://ccsvivictory.club.officelive.com/ConflictsofInterest.aspx
The four new cases of PML only makes things worse.
Recs
Recs
Contralogic
(< 20)
Submitted: 1/23/2010 10:19:08 AM :
Start Price:
$8.05
ELN Score:
+37.71
Elan -- will be a player in the biotech across the next 5 years.
Recs
wanttobelieve
(< 20)
Submitted: 12/14/2009 11:58:41 PM :
Start Price:
$6.45
ELN Score:
-78.68
Elan as a supply company is terrible!!! They are unable to manufacture and supply their own products. Take Azactam (aztreonam) an injectable antibiotic used in hospitals for example. They have a patent protection on the drug and yet have been unable to manufacture and supply it FOR OVER A YEAR!! If this is how the handle their research function then I want no part of it!
Recs
rainmaker59
(69.33)
Submitted: 11/11/2009 9:29:44 PM :
Start Price:
$6.32
ELN Score:
+81.18
Rulebreaker pick of Jan. 2009. All debt is related to massive R&D expenses. Leading edge of RX for Crohn's, MS and Alzheimer's.
Recs
macginty
(< 20)
Submitted: 10/29/2009 1:43:34 PM :
Start Price:
$5.19
ELN Score:
+121.34
The reason I feel that Eln will outperform is due to the underlying strength of a number of product lines in it's poertfolio e.g. the negative publicity regarding PML and Tysabri is exagerated and ignores the positive impact of the treatment on many lives.
Recs
Oaklander
(< 20)
Submitted: 10/23/2009 3:28:21 PM :
Start Price:
$5.34
ELN Score:
+116.09
Elan was hit hard today with some foul news out of Europe, but this shall pass. Tysabri has proven to have a high level of efficacy in the treatment of MS. In fact, it is the MOST effective treatment on the market today. Combined with some exciting Alzheimer's treatments coming down the line (Bapineuzumab, et al) and ongoing research into Parkinson's, Elan will certainly return handsomely given a few years.
Recs
pjani06
(54.51)
Submitted: 10/9/2009 2:18:35 AM :
Start Price:
$6.80
ELN Score:
+62.98
per wallst tracker edwardowens
Recs
KARABALIS
(< 20)
Submitted: 10/6/2009 10:16:47 AM :
Start Price:
$6.89
ELN Score:
+59.16
Elan has the right research, great partners and good management. All they need is a little cooperation from the FDA and a bit of luck.
Recs
Ptimespec
(< 20)
Submitted: 9/18/2009 10:42:29 AM :
Start Price:
$7.36
ELN Score:
+48.56
This stock is extremely speculative, however, the pipeline for Alzimers and the very successful rollout of Tysbari will generate huge interest in the back end of 2009 and begining of 2010. Clearing its liquidity issue through this J&J deal will clear the way for news flow to bring this stock back to 2004 and 2008 levels, or at least fairly close to those peaks.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 197 : 1 2 3 4 5 6 7 8 9 10 Next »